GSK CEO warns possible team reorganization if upcoming Phase 3 readouts fall short
read at Endpoints ↗Neutral
GSK's chief executive Luke Miels told analysts during the first‑quarter earnings call that the company has several pivotal Phase 3 trials slated for this year.
He said that if those late‑stage readouts do not meet expectations, GSK may consider reshaping its team structure to better align with future priorities.
The comment underscores the importance of the upcoming data for the company's strategic direction, but no specific drugs or timelines were disclosed.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts”
read at Endpoints ↗92 words · retrieved Apr 29
comments(0)
5-min edit window · permanent after that